High-resolution epigenomic liquid biopsy for noninvasive phenotyping in pregnancy

Prenat Diagn. 2021 Jan;41(1):61-69. doi: 10.1002/pd.5833. Epub 2020 Oct 10.

Abstract

Objective: We explored the potential of genome-wide epigenomic liquid biopsy for the comprehensive analysis of cell-free DNA (cfDNA) methylation signatures in maternal plasma in early gestation.

Method: We used solution phase hybridization for targeted region capture of bisulfite-converted DNA obtained from plasma of pregnant women in early gestation and nonpregnant female controls.

Results: Targeted sequencing of ~80.5 Mb of the plasma methylome generated an average read depth across all 17 plasma samples of ~42x. We used these data to explore the pregnancy-specific characteristics of cfDNA methylation in plasma and found that pregnancy resulted in clearly detectable global alterations in DNA methylation patterns that were influenced by genomic location. We analyzed similar, previously published, data from first-trimester maternal leukocyte populations and gestational age-matched chorionic villus (CV) and confirmed that tissue-specific DNA methylation signatures in these samples had a significant influence on global and gene-specific methylation in the plasma of pregnant women.

Conclusion: We describe an approach for targeted epigenomic liquid biopsy in pregnancy and discuss our findings in the context of noninvasive prenatal testing with respect to phenotypic pregnancy monitoring and the early detection of complex gestational phenotypes such as preeclampsia and preterm birth.

MeSH terms

  • Case-Control Studies
  • Cell-Free Nucleic Acids / analysis*
  • CpG Islands
  • DNA Methylation*
  • Epigenomics / methods*
  • Female
  • Humans
  • Maternal Serum Screening Tests
  • Noninvasive Prenatal Testing / methods*
  • Pregnancy / metabolism*

Substances

  • Cell-Free Nucleic Acids